Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Percocet	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Chills	O
after	O
ureteral	O
stent	O
placement	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
___:	O
Cystoscopy	O
with	O
left	O
double-J	O
stent	O
placement	O
History	O
of	O
Present	O
Illness:	O
This	O
___	O
year-old	O
woman	O
with	O
PMH	O
significant	O
for	O
type	O
2	O
diabetes,	O
hypertension,	O
and	O
PAF	O
who	O
was	O
in	O
her	O
usual	O
state	O
of	O
health	O
until	O
approximately	O
9	O
months	O
ago	O
(___,	O
when	O
she	O
began	O
to	O
experience	O
weight	B-Weight_loss
loss	B-Weight_loss
due	O
to	O
diminished	O
appetite.	O
In	O
___	O
she	O
developed	O
GI	O
distress	O
and	O
melanotic	B-Upper_gastrointestinal_haemorrhage
stools.	O
She	O
was	O
admitted	O
to	O
___	O
for	O
one	O
night	O
on	O
___	O
complaining	O
of	O
several	O
months	O
of	O
melena	B-Upper_gastrointestinal_haemorrhage
and	O
a	O
25lb	O
weight	B-Weight_loss
loss.	B-Weight_loss
She	O
was	O
briefly	O
admitted	O
to	O
a	O
hospital	O
in	O
___,	O
where	O
an	O
EGD	O
disclosed	O
ulcers.	O
She	O
was	O
treated	O
for	O
these	O
but	O
continued	O
to	O
have	O
diarrhea,	O
without	O
melena.	B-Upper_gastrointestinal_haemorrhage
Overall,	O
she	O
has	O
lost	B-Weight_loss
a	O
total	O
of	O
30	O
lbs,	O
or	O
20%	O
of	O
her	O
body	O
weight.	B-Weight_loss
She	O
returned	O
from	O
___	O
in	O
___	O
and	O
underwent	O
colonoscopy	O
here	O
at	O
___	O
on	O
___	O
showing	O
severe-appearing	O
sigmoid	O
diverticulosis.	O
As	O
the	O
sigmoid	O
colon	O
appeared	O
fixed,	O
more	O
proximal	O
colon	O
was	O
not	O
visualized.	O
Virtual	O
colonography	O
on	O
___	O
revealed	O
a	O
3.4	O
x	O
2.7	O
cm	O
left	O
para-aortic	O
mass	O
with	O
associated	O
left	O
side	O
hydronephrosis.	O
EUS	O
on	O
___	O
identified	O
a	O
round	O
1.5cm	O
para-aortic	O
node	O
with	O
an	O
adjacent	O
irregular	O
3.5	O
x	O
3.5	O
cm	O
hypoechoic	O
mass	O
with	O
hyperechoic	O
foci.	O
Both	O
masses	O
abutted	O
the	O
aorta.	O
FNA	O
of	O
the	O
mass	O
on	O
___	O
was	O
consistent	O
with	O
poorly	O
differentiated	O
adenocarcinoma.	O
A	O
staging	O
torso	O
CT	O
on	O
___	O
showed	O
only	O
several	O
pulmonary	O
nodules	O
~1cm	O
in	O
diameter,	O
and	O
severe	O
left	O
hydronephrosis.	O
GU	O
U/S	O
confirmed	O
the	O
left	O
hydroureteronephrosis,	O
presumed	O
secondary	O
to	O
the	O
para-aortic	O
lymphadenopathy.	O
She	O
was	O
admitted	O
and	O
underwent	O
ureteral	O
stent	O
placement	O
on	O
___.	O
Though	O
the	O
procedure	O
was	O
uncomplicated,	O
about	O
10min	O
afterwards	O
she	O
reported	O
chills	O
and	O
tachycardia.	O
She	O
was	O
admitted	O
to	O
the	O
urology	O
service.	O
Past	O
Medical	O
History:	O
1.	O
Type	O
2	O
diabetes	O
mellitus	O
2.	O
Hypothyroidism	O
3.	O
Hypertension	O
4.	O
Hypercholesterolemia	O
5.	O
Glaucoma	O
6.	O
Osteoarthritis	O
7.	O
Irritable	O
bowel	O
syndrome	O
8.	O
Glaucoma	O
9.	O
Decreased	B-Hearing_impairment
hearing	B-Hearing_impairment
10.	O
Osteopenia	O
11.	O
Paroxysmal	O
Atrial	O
Fibrillation	O
PAST	O
SURGICAL	O
HISTORY:	O
1.	O
Status	O
post	O
cholecystectomy	O
-	O
___	O
2.	O
Status	O
post	O
appendectomy	O
3.	O
Status	O
post	O
hysterectomy	O
for	O
amenorrhea	O
-	O
In	O
her	O
___.	O
4.	O
Status	O
post	O
bilateral	O
cataract	O
removal	O
5.	O
Status	O
post	O
right	O
knee	O
replacement	O
-	O
___.	O
Social	O
History:	O
___	O
Family	O
History:	O
Mother	O
-	O
died	O
of	O
an	O
MI	O
at	O
age	O
___,	O
osteoporosis	O
Father	O
-	O
died	O
in	O
his	O
___	O
of	O
lung	O
cancer	O
Brother	O
-	O
died	O
of	O
lung	O
cancer.	O
Physical	O
Exam:	O
T	O
97.0	O
/	O
BP	O
126/80	O
/	O
HR	O
79	O
and	O
regular	O
/	O
RR	O
18	O
/	O
SaO2	O
99%	O
RA	O
GENL:	O
NAD,	O
resting	O
comfortably	O
in	O
bed,	O
speaking	O
clearly	O
HEENT:	O
NC/AT,	O
clear	O
OP,	O
MMM,	O
EOMI	O
NECK:	O
Supple,	O
no	O
JVD;	O
No	O
cervical,	O
occipital,	O
supraclavicular	O
LAD	O
CV:	O
RRR,	O
no	O
MRG.	O
NL	O
S1,	O
S2	O
LUNGS:	O
CTAB	O
ABD:	O
Soft,	O
NT,	O
ND.	O
NL	O
BS.	O
Nontender	O
to	O
palpation	O
over	O
the	O
circumferential	O
suprapubic	O
band	O
she	O
describes	O
pain	O
in.	O
No	O
HSM.	O
EXT:	O
No	O
edema.	O
2+	O
DP	O
pulses	O
bilaterally	O
SKIN:	O
No	O
rashes	O
NEURO:	O
Non-focal	O
PSYCH:	O
Listens	O
and	O
responds	O
to	O
questions	O
appropriately,	O
pleasant	O
Pertinent	O
Results:	O
LABS:	O
___	O
07:00AM	O
BLOOD	O
WBC-11.4*	O
RBC-3.87*	O
Hgb-10.6*	O
Hct-32.3*	O
MCV-83	O
MCH-27.4	O
MCHC-32.9	O
RDW-13.7	O
Plt	O
___	O
___	O
07:00AM	O
BLOOD	O
Glucose-74	O
UreaN-19	O
Creat-0.7	O
Na-139	O
K-3.9	O
Cl-106	O
HCO3-22	O
AnGap-15	O
___	O
07:10AM	O
BLOOD	O
ALT-6	O
AST-14	O
AlkPhos-77	O
Amylase-31	O
TotBili-0.3	O
___	O
07:00AM	O
BLOOD	O
Calcium-8.2*	O
Phos-2.3*	O
Mg-1.6	O
MICROBIOLOGY:	O
___	O
STOOL	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST:	O
NEGATIVE	O
___	O
STOOL	O
CLOSTRIDIUM	O
DIFFICILE	O
TOXIN	O
A	O
&	O
B	O
TEST:	O
NEGATIVE	O
___	O
BLOOD	O
CULTURES	O
-	O
NO	O
GROWTH	O
TO	O
DATE	O
___	O
URINE	O
CULTURE	O
(Final	O
___	O
(NOT	O
SENT	O
WHILE	O
INPATIENT):	O
Culture	O
workup	O
discontinued.	O
Further	O
incubation	O
showed	O
contamination	O
with	O
mixed	O
skin/genital	O
flora.	O
Clinical	O
significance	O
of	O
isolate(s)	O
uncertain.	O
Interpret	O
with	O
caution.	O
ESCHERICHIA	O
COLI.	O
>100,000	O
ORGANISMS/ML..	O
PRESUMPTIVE	O
IDENTIFICATION.	O
SENSITIVITIES:	O
MIC	O
expressed	O
in	O
MCG/ML	O
_________________________________________________________	O
ESCHERICHIA	O
COLI	O
|	O
AMPICILLIN------------	O
=>32	O
R	O
AMPICILLIN/SULBACTAM--	O
4	O
S	O
CEFAZOLIN-------------	O
<=4	O
S	O
CEFEPIME--------------	O
<=1	O
S	O
CEFTAZIDIME-----------	O
<=1	O
S	O
CEFTRIAXONE-----------	O
<=1	O
S	O
CIPROFLOXACIN---------	O
=>4	O
R	O
GENTAMICIN------------	O
<=1	O
S	O
MEROPENEM-------------<=0.25	O
S	O
NITROFURANTOIN--------	O
<=16	O
S	O
PIPERACILLIN/TAZO-----	O
<=4	O
S	O
TOBRAMYCIN------------	O
<=1	O
S	O
TRIMETHOPRIM/SULFA----	O
<=1	O
S	O
IMAGING:	O
___	O
CXR:	O
Lung	O
volumes	O
are	O
slightly	O
low	O
causing	O
mild	O
bronchovascular	O
crowding,	O
particularly	O
at	O
the	O
bases.	O
There	O
is	O
no	O
focal	O
consolidation,	O
pleural	O
effusion	O
or	O
pneumothorax.	O
Multiple	O
pulmonary	O
nodules	O
better	O
seen	O
on	O
the	O
recent	O
CT	O
torso	O
are	O
again	O
noted.	O
There	O
is	O
no	O
adenopathy.	O
Heart	O
size	O
is	O
normal.	O
There	O
is	O
no	O
pulmonary	O
edema.	O
Aortic	O
contour	O
is	O
unfolded.	O
There	O
is	O
a	O
left	O
ureteral	O
stent,	O
partially	O
visualized.	O
___	O
RENAL	O
U/S:	O
The	O
right	O
kidney	O
measures	O
9.5	O
cm.	O
The	O
left	O
kidney	O
measures	O
10.0	O
cm.	O
There	O
is	O
no	O
hydronephrosis	O
in	O
either	O
side,	O
with	O
apparent	O
interval	O
resolution	O
of	O
the	O
left	O
hydronephrosis.	O
The	O
left	O
ureteral	O
stent	O
is	O
vaguely	O
visible	O
at	O
the	O
left	O
UPJ.	O
A	O
punctate	O
2-mm	O
echogenic	O
foci	O
noted	O
in	O
the	O
left	O
mid	O
pole,	O
without	O
posterior	O
shadowing,	O
non-specific	O
and	O
could	O
represent	O
a	O
portion	O
of	O
the	O
ureteral	O
stent	O
or	O
a	O
tiny	O
non-obstructive,	O
non-shadowing	O
stone.	O
There	O
is	O
no	O
perinephric	O
fluid	O
collection.	O
A	O
hypoechoic	O
area	O
is	O
noted	O
posterior	O
to	O
and	O
distinct	O
from	O
the	O
left	O
kidney,	O
could	O
represent	O
the	O
psoas	O
muscle	O
or	O
the	O
known	O
retroperitoneal	O
lymphadenopathy.	O
The	O
non-fully	O
distended	O
bladder	O
is	O
noted	O
with	O
a	O
small	O
amount	O
of	O
debris	O
in	O
the	O
dependent	O
portion.	O
___	O
RETROGRADE	O
UROGRAPHY	O
(FILMS	O
FROM	O
CYSTO):	O
There	O
is	O
evidence	O
of	O
left	O
hydronephrosis	O
with	O
blunting	O
of	O
the	O
calices.	O
A	O
left	O
ureteral	O
stent	O
was	O
placed	O
with	O
proximal	O
tip	O
in	O
the	O
renal	O
pelvis,	O
distal	O
tip	O
is	O
not	O
seen	O
on	O
the	O
fluoroscopic	O
images.	O
Brief	O
Hospital	O
Course:	O
This	O
is	O
an	O
___	O
year-old	O
woman	O
with	O
para-aortic	O
retroperitoneal	O
masses	O
found	O
on	O
FNA	O
to	O
be	O
poorly	O
differentiated	O
adenocarcinoma	O
of	O
unknown	O
origin,	O
and	O
causing	O
partial	O
obstruction	O
of	O
her	O
left	O
ureter	O
leading	O
to	O
left	O
hydronephrosis.	O
She	O
presented	O
on	O
___	O
for	O
outpatient	O
left	O
ureteral	O
stent	O
placement.	O
Though	O
the	O
procedure	O
was	O
uncomplicated,	O
she	O
reported	O
chills	O
and	O
tachycardia	O
shortly	O
afterwards.	O
She	O
was	O
started	O
empirically	O
on	O
vancomycin,	O
cefepime,	O
and	O
metronidazole	O
and	O
was	O
admitted	O
to	O
urology.	O
Of	O
note,	O
urine	O
cultures	O
from	O
___	O
had	O
grown	O
ciprofloxacin	O
and	O
ampicillin	O
resistant	O
E.	O
coli.	O
She	O
also	O
developed	O
a	O
large	O
amount	O
of	O
diarrhea	O
later	O
on	O
the	O
day	O
of	O
the	O
procedure.	O
Despite	O
the	O
antibiotics	O
her	O
WBC	O
rose	O
from	O
19	O
to	O
34	O
before	O
beginning	O
to	O
trend	O
down.	O
She	O
was	O
transferred	O
to	O
medicine	O
on	O
___,	O
at	O
which	O
time	O
her	O
WBC	O
was	O
back	O
to	O
19.	O
Her	O
coverage	O
was	O
narrowed	O
according	O
to	O
sensitivities.	O
#	O
Leukocytosis.	O
Given	O
the	O
positive	O
cultures,	O
it	O
is	O
likely	O
the	O
minor	O
trauma	O
of	O
the	O
procedure	O
allowed	O
enough	O
bacterial	O
translocation	O
to	O
allow	O
a	O
transient	O
GN	O
bacteremia	O
with	O
consequent	O
leukemoid	O
reaction.	O
Blood	O
cultures	O
from	O
the	O
day	O
of	O
procedure	O
remain	O
negative.	O
Given	O
her	O
diarrhea	O
and	O
numerous	O
recent	O
hospitalizations,	O
C.	O
difficile	O
was	O
considered	O
as	O
an	O
explanation	O
of	O
her	O
leukocytosis;	O
two	O
studies	O
were	O
sent,	O
both	O
negative.	O
Her	O
WBC	O
continued	O
to	O
trend	O
down	O
to	O
11	O
on	O
morning	O
of	O
discharge.	O
She	O
was	O
asymptomatic	O
from	O
___	O
until	O
her	O
discharge	O
on	O
___.	O
#	O
Complicated	O
urinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infection.	B-Urinary_tract_infection
While	O
she	O
did	O
endorse	O
some	O
cloudy	O
urine	O
prior	O
to	O
her	O
stent	O
placement,	O
she	O
denied	O
any	O
UTI	B-Urinary_tract_infection
symptoms	O
after	O
admisson.	O
Despite	O
her	O
high	O
WBC,	O
she	O
was	O
afebrile	O
and	O
stable	O
on	O
the	O
floor.	O
Sensitivities	O
on	O
the	O
___	O
urine	O
culture	O
showed	O
the	O
E.	O
coli	O
to	O
be	O
bactrim	O
sensitive,	O
so	O
we	O
narrowed	O
coverage	O
to	O
bactrim	O
for	O
a	O
14	O
day	O
course.	O
Follow	O
up	O
urine	O
studies	O
on	O
___	O
showed	O
E.	O
coli	O
at	O
3000/ml.	O
U/A	O
from	O
the	O
same	O
day	O
showed	O
68	O
WBC.	O
She	O
was	O
remained	O
afebrile	O
on	O
the	O
floor,	O
with	O
a	O
decreasing	O
WBC.	O
She	O
is	O
advised	O
to	O
be	O
on	O
the	O
lookout	O
for	O
UTI	B-Urinary_tract_infection
symptoms,	O
as	O
her	O
altered	O
anatomy	O
and	O
stent	O
place	O
her	O
at	O
higher	O
risk	O
of	O
infection.	O
Follow	O
up	O
U/S	O
on	O
___	O
showed	O
interval	O
resolution	O
of	O
the	O
left	O
hydronephrosis.	O
She	O
will	O
follow	O
up	O
with	O
Dr.	O
___	O
urology	O
on	O
___.	O
#	O
Carcinoma	O
of	O
unknown	O
primary.	O
She	O
expressed	O
a	O
thorough	O
understanding	O
of	O
her	O
malignancy,	O
including	O
the	O
uncertainty	O
of	O
the	O
diagnosis.	O
She	O
was	O
inclined	O
to	O
go	O
on	O
family	O
vacation	O
to	O
___	O
before	O
addressing	O
the	O
issue	O
further.	O
She	O
is	O
scheduled	O
with	O
for	O
CT	O
guided	O
biopsy	O
on	O
___.	O
She	O
will	O
see	O
her	O
PCP,	O
___.	O
___,	O
on	O
___	O
at	O
this	O
meeting	O
they	O
will	O
discuss	O
oncological	O
follow-up.	O
#	O
Paroxysmal	O
atrial	O
fibrillation.	O
On	O
the	O
floor,	O
she	O
became	O
tachycardic	O
to	O
the	O
140s.	O
She	O
received	O
5mg	O
IV	O
metoprolol,	O
and	O
shortly	O
thereafter	O
regained	O
NSR.	O
She	O
remained	O
in	O
NSR	O
until	O
discharge.	O
We	O
maintained	O
her	O
on	O
metoprolol	O
25mg	O
BID	O
after	O
the	O
episode	O
of	O
atrial	O
fibrillation.	O
As	O
her	O
baseline	O
heart	O
rate	O
was	O
in	O
the	O
___	O
and	O
systolic	O
blood	O
pressure	O
in	O
the	O
130s,	O
we	O
added	O
metoprolol	O
XL	O
50mg	O
to	O
her	O
discharge	O
medications.	O
As	O
she	O
was	O
asymptomatic	O
throughout,	O
it	O
is	O
unclear	O
how	O
often	O
these	O
events	O
occur.	O
We	O
noted	O
that	O
she	O
is	O
CHADS	O
3	O
and	O
could	O
benefit	O
from	O
coumadin,	O
though	O
her	O
recent	O
history	O
of	O
melena	O
does	O
complicate	O
this	O
decision	O
and	O
it	O
should	O
be	O
readdressed	O
as	O
an	O
outpatient.	O
She	O
was	O
continued	O
on	O
aspirin	O
only.	O
#	O
Abdominal	O
pain.	O
She	O
complained	O
of	O
a	O
circumferential	O
painful	O
band,	O
non-tender	O
to	O
palpation,	O
over	O
the	O
abdomen	O
extending	O
from	O
pubis	O
to	O
umbilicus.	O
This	O
could	O
be	O
due	O
to	O
stretch	O
on	O
her	O
left	O
kidney	O
capsule,	O
or	O
due	O
to	O
direct	O
involvement	O
of	O
nerve	O
roots	O
by	O
her	O
retroperitoneal	O
mass.	O
If	O
the	O
former,	O
her	O
pain	O
may	O
improve	O
secondary	O
to	O
the	O
stent.	O
In	O
either	O
case,	O
she	O
endorsed	O
improvement	O
with	O
lidocaine	O
patch	O
and	O
with	O
tramadol.	O
She	O
was	O
discharged	O
with	O
both	O
of	O
these	O
medications.	O
#	O
Type	O
2	O
diabetes	O
mellitus.	O
Her	O
blood	O
glucoses	O
were	O
stable	O
during	O
this	O
admission.	O
We	O
maintained	O
her	O
home	O
glipizide	O
and	O
metformin.	O
She	O
received	O
no	O
insulin.	O
#	O
Weight	B-Weight_loss
loss.	B-Weight_loss
This	O
is	O
likely	O
secondary	O
to	O
her	O
malignancy	O
and	O
to	O
her	O
persistent	O
diarrhea.	O
Her	O
appetite	O
is	O
significantly	O
reduced.	O
We	O
advised	O
her	O
to	O
eat	O
what	O
she	O
can	O
tolerate,	O
and	O
to	O
supplement	O
her	O
diet	O
with	O
calorie	O
rich	O
liquids	O
such	O
as	O
Ensure.	O
#	O
Diarrhea.	O
She	O
developed	O
some	O
significant	O
diarrhea	O
after	O
the	O
stent	O
placement.	O
Inasmuch	O
as	O
she	O
has	O
some	O
diarrhea	O
at	O
baseline,	O
we	O
felt	O
it	O
was	O
unlikely	O
an	O
infectious	O
etiology.	O
However,	O
given	O
her	O
recent	O
hospitalizations	O
we	O
sent	O
two	O
C.	O
difficile	O
studies,	O
both	O
negative.	O
Though	O
her	O
stools	O
remained	O
somewhat	O
loose,	O
the	O
diarrhea	O
she	O
experienced	O
on	O
the	O
day	O
of	O
the	O
stent	O
placement	O
did	O
not	O
recur.	O
#	O
Hypertension,	O
hyperlipidemia,	O
glaucoma,	O
osteopenia,	O
hypothyroidism.	O
These	O
problems	O
were	O
stable.	O
We	O
maintained	O
home	O
medications.	O
Medications	O
on	O
Admission:	O
1.	O
Aspirin	O
81	O
mg	O
2.	O
Calcium	O
Carbonate	O
500	O
mg	O
Tablet	O
BID	O
3.	O
Omega-3	O
Fatty	O
Acids	O
one	O
capsule	O
daily	O
4.	O
Glipizide	O
5	O
mg	O
Tablet	O
Sig:	O
0.25	O
Tablet	O
PO	O
BID	O
5.	O
Levothyroxine	O
50	O
mcg	O
Tablet	O
daily	O
6.	O
Metformin	O
500	O
mg	O
Tablet	O
PO	O
BID	O
7.	O
Multivitamin	O
8.	O
Cholecalciferol	O
(Vitamin	O
D3)	O
1,000	O
unit	O
Tablet	O
PO	O
Daily	O
9.	O
Simvastatin	O
20	O
mg	O
PO	O
DAILY	O
10.	O
Latanoprost	O
0.005	O
%	O
Drops	O
Sig:	O
One	O
(1)	O
Drop	O
Ophthalmic	O
QHS	O
11.	O
Lisinopril	O
20	O
mg	O
Tablet	O
daily	O
12.	O
Tylenol	O
Extra	O
Strength	O
1000	O
mg	O
PO	O
TID	O
PRN	O
pain	O
Discharge	O
Medications:	O
1.	O
Omega-3	O
Fatty	O
Acids	O
1,000	O
mg	O
Capsule	O
Sig:	O
One	O
(1)	O
Capsule	O
PO	O
once	O
a	O
day.	O
2.	O
Levothyroxine	O
50	O
mcg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
3.	O
Metformin	O
500	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day).	O
4.	O
Multivitamin	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
5.	O
Latanoprost	O
0.005	O
%	O
Drops	O
Sig:	O
One	O
(1)	O
Drop	O
Ophthalmic	O
HS	O
(at	O
bedtime).	O
6.	O
Lisinopril	O
20	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
DAILY	O
(Daily).	O
7.	O
Tylenol	O
Extra	O
Strength	O
500	O
mg	O
Tablet	O
Sig:	O
___	O
Tablets	O
PO	O
three	O
times	O
a	O
day	O
as	O
needed	O
for	O
fever	O
or	O
pain.	O
8.	O
Lidocaine	O
5	O
%(700	O
mg/patch)	O
Adhesive	O
Patch,	O
Medicated	O
Sig:	O
One	O
(1)	O
Adhesive	O
Patch,	O
Medicated	O
Topical	O
DAILY	O
(Daily)	O
as	O
needed	O
for	O
Pain:	O
Apply	O
for	O
12	O
hours	O
daily	O
.	O
Disp:*30	O
Adhesive	O
Patch,	O
Medicated(s)*	O
Refills:*0*	O
9.	O
Zofran	O
4	O
mg	O
Tablet	O
Sig:	O
___	O
Tablets	O
PO	O
every	O
twelve	O
(12)	O
hours	O
as	O
needed	O
for	O
nausea.	O
Disp:*12	O
Tablet(s)*	O
Refills:*0*	O
10.	O
Tramadol	O
50	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
every	O
six	O
(6)	O
hours	O
as	O
needed	O
for	O
pain.	O
Disp:*30	O
Tablet(s)*	O
Refills:*0*	O
11.	O
Sulfamethoxazole-Trimethoprim	O
800-160	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
BID	O
(2	O
times	O
a	O
day)	O
for	O
10	O
days.	O
Disp:*20	O
Tablet(s)*	O
Refills:*0*	O
12.	O
Metoprolol	O
Succinate	O
50	O
mg	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
Sig:	O
One	O
(1)	O
Tablet	O
Sustained	O
Release	O
24	O
hr	O
PO	O
once	O
a	O
day.	O
Disp:*30	O
Tablet	O
Sustained	O
Release	O
24	O
hr(s)*	O
Refills:*0*	O
13.	O
Aspirin	O
81	O
mg	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
Sig:	O
One	O
(1)	O
Tablet,	O
Delayed	O
Release	O
(E.C.)	O
PO	O
once	O
a	O
day.	O
14.	O
Glipizide	O
5	O
mg	O
Tablet	O
Sig:	O
___	O
Tablet	O
PO	O
twice	O
a	O
day.	O
15.	O
Calcium	O
500	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
twice	O
a	O
day.	O
16.	O
Vitamin	O
D	O
1,000	O
unit	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
17.	O
Simvastatin	O
20	O
mg	O
Tablet	O
Sig:	O
One	O
(1)	O
Tablet	O
PO	O
once	O
a	O
day.	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
Primary:	O
Left	O
hydronephrosis,	O
E.	O
coli	O
urinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infection	B-Urinary_tract_infection
Secondary:	O
Paroxysmal	O
atrial	O
fibrillation,	O
carcinoma	O
of	O
unknown	O
origin,	O
type	O
II	O
diabetes	O
mellitus	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	O
requires	O
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
You	O
initially	O
came	O
to	O
___	O
for	O
placement	O
of	O
a	O
stent	O
in	O
your	O
ureter,	O
the	O
tube	O
connecting	O
the	O
kidney	O
to	O
the	O
bladder.	O
This	O
stent	O
was	O
placed	O
to	O
relieve	O
pressure	O
on	O
your	O
left	O
kidney.	O
Imaging	O
since	O
placement	O
of	O
the	O
stent	O
shows	O
that	O
the	O
pressure	O
on	O
your	O
kidney	O
has	O
begun	O
to	O
resolve.	O
After	O
placement	O
of	O
the	O
stent	O
you	O
began	O
experiencing	O
chills.	O
We	O
started	O
treating	O
you	O
with	O
antibiotics.	O
Studies	O
of	O
your	O
blood	O
showed	O
that	O
your	O
white	O
blood	O
cell	O
count	O
was	O
increased;	O
these	O
are	O
the	O
cells	O
that	O
fight	O
infection.	O
Looking	O
back	O
at	O
your	O
records,	O
you	O
had	O
had	O
evidence	O
of	O
a	O
urinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infection	B-Urinary_tract_infection
prior	O
to	O
your	O
stent	O
placement.	O
It	O
is	O
likely	O
that	O
some	O
of	O
the	O
bacteria	O
causing	O
that	O
infection	O
were	O
able	O
to	O
enter	O
your	O
bloodstream	O
during	O
the	O
procedure,	O
which	O
caused	O
your	O
symptoms	O
and	O
the	O
elevation	O
in	O
white	O
blood	O
cells.	O
After	O
initiating	O
antibiotics,	O
your	O
symptoms	O
resolved,	O
you	O
have	O
been	O
afebrile,	O
and	O
your	O
white	O
blood	O
cell	O
count	O
has	O
decreased.	O
We	O
changed	O
you	O
to	O
an	O
antibiotic	O
called	O
bactrim	O
that	O
is	O
commonly	O
used	O
to	O
treat	O
urinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infections.	B-Urinary_tract_infection
You	O
also	O
continued	O
to	O
experience	O
pain	O
around	O
your	O
abdomen	O
in	O
a	O
band-like	O
pattern.	O
This	O
may	O
be	O
due	O
to	O
the	O
enlarged	O
kidney,	O
and	O
may	O
resolve	O
now	O
that	O
the	O
ureteral	O
stent	O
is	O
in	O
place.	O
It	O
may	O
also	O
be	O
due	O
to	O
the	O
enlarged	O
lymph	O
nodes	O
triggering	O
your	O
pain	O
receptors.	O
You	O
found	O
that	O
a	O
lidocaine	O
patch	O
helped	O
with	O
the	O
pain.	O
On	O
the	O
floor,	O
you	O
had	O
an	O
episode	O
of	O
atrial	O
fibrillation	O
causing	O
your	O
heart	O
rate	O
to	O
increase.	O
We	O
gave	O
you	O
a	O
medication	O
called	O
metoprolol,	O
which	O
slowed	O
your	O
heart	O
rate.	O
You	O
resumed	O
a	O
normal	O
hearth	O
rhythm	O
for	O
the	O
remainder	O
of	O
your	O
stay.	O
Please	O
note	O
the	O
following	O
changes	O
to	O
your	O
medications:	O
-	O
Please	O
continue	O
to	O
take	O
metoprolol	O
as	O
directed;	O
this	O
is	O
a	O
small	O
dose.	O
Dr.	O
___	O
assess	O
the	O
need	O
for	O
continuing	O
this	O
medication	O
at	O
your	O
next	O
appointment.	O
-	O
For	O
pain,	O
continue	O
to	O
use	O
the	O
lidocaine	O
patch,	O
tylenol,	O
and	O
tramadol	O
as	O
needed.	O
Please	O
do	O
not	O
take	O
more	O
than	O
3000mg	O
of	O
the	O
tylenol	O
daily	O
as	O
it	O
can	O
cause	O
damage	O
to	O
your	O
liver.	O
-	O
Please	O
take	O
zofran	O
as	O
needed	O
for	O
nausea.	O
-	O
Please	O
continue	O
to	O
take	O
your	O
other	O
medications	O
as	O
you	O
did	O
prior	O
to	O
your	O
hospitalization.	O
The	O
following	O
appointments	O
have	O
been	O
made	O
for	O
you:	O
-	O
CT	O
guided	O
biopsy:	O
Please	O
come	O
to	O
the	O
___	O
floor	O
of	O
the	O
___	O
building	O
on	O
the	O
___	O
on	O
___	O
at	O
9:00	O
AM.	O
Your	O
biopsy	O
will	O
take	O
place	O
later	O
on	O
the	O
same	O
day,	O
___,	O
in	O
the	O
___	O
floor	O
of	O
the	O
___	O
building	O
at	O
10:30AM.	O
-	O
Dr.	O
___:	O
Please	O
see	O
Dr.	O
___	O
on	O
___,	O
8:30	O
AM,	O
on	O
the	O
___	O
floor	O
of	O
the	O
___	O
building.	O
-	O
Dr.	O
___:	O
Please	O
see	O
Dr.	O
___	O
on	O
the	O
___	O
floor	O
of	O
the	O
___	O
on	O
___	O
at	O
10:30AM.	O
Followup	O
Instructions:	O
___	O

